RIN Institute Inc

Our company was established in January 2016, for development of anti-cancer antibody drugs both for therapeutic as well as diagnostic uses based upon the research results by Yasuhiro Matsumura, Chief of Division of Developmental Therapeutics, EPOC, National Cancer Center (NCC). In March of the same year, we were certified as a spin-out venture from NCC. Our research laboratory is a research base to promote efficient collaboration with NCC. We will accelerate development of new innovative antibodies for anti-cancer drugs and diagnostic drugs with the support of NCC.

Shintomi Bldg 3F, 2-5-10 Shintomi Chuo-ku, Tokyo, 104-0041, Japan
E-Mail：info●rinmab.co.jp（●を＠に置き換えてください）
URL：https://rinmab.co.jp/